A novel polymerase β inhibitor from phage displayed peptide library augments the anti-tumour effects of temozolomide on colorectal cancer

References

• Nappi A, Berretta M, Romano C, et al. Metastatic colorectal cancer: role of target therapies and future perspectives. Curr Cancer Drug Targets. 2017.
   Web of Science ®Google Scholar
• Ray K. Gut microbiota: colorectal cancer-driven by inflammation and gut bacteria? Nat Rev Gastroenterol Hepatol. 2012;9(10):558.
   PubMedGoogle Scholar
• Brower V. Modified gastric cancer chemotherapy: more effective, less toxic. Lancet Oncol. 2015;16(16):e590.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000;6(7):2585–2597.
   PubMed Web of Science ®Google Scholar
• Tang J-B, Svilar D, Trivedi RN, et al. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro Oncol. 2011;13(5):471–486.
   PubMed Web of Science ®Google Scholar
• Wood RD, Mitchell M, Sgouros J, et al. Human DNA repair genes. Science. 2001;291(5507):1284–1289.
   PubMed Web of Science ®Google Scholar
• Donigan KA, Hile SE, Eckert KA, et al. The human gastric cancer-associated DNA polymerase β variant D160N is a mutator that induces cellular transformation. DNA Repair (Amst). 2012;11(4):381–390.
   PubMed Web of Science ®Google Scholar
• Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol. 2004;31(5):635–644.
   PubMed Web of Science ®Google Scholar
• Tentori L, Graziani G. Pharmacological strategies to increase the antitumor activity of methylating agents. Curr Med Chem. 2002;9(13):1285–1301.
   PubMed Web of Science ®Google Scholar
• Dronca RS, Allred JB, Perez DG, et al. Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central cancer treatment group study, N0675. Am J Clin Oncol. 2014;37(4):369–376.
   PubMed Web of Science ®Google Scholar
• Newlands ES, Foster T, Zaknoen S. Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer. 2003;89(2):248–251.
   PubMed Web of Science ®Google Scholar
• Affronti ML, Woodring S, Allen K, et al. Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). Support Care Cancer. 2016;24(10):4365–4375.
   PubMed Web of Science ®Google Scholar
• Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193–204.
   PubMed Web of Science ®Google Scholar
• Wallace SS. Base excision repair: a critical player in many games. DNA Repair (Amst). 2014;19:14–26.
   PubMed Web of Science ®Google Scholar
• (a) Grundy GJ, Parsons JL. Base excision repair and its implications to cancer therapy. Essays Biochem. 2020;64:831. (b) Grundy GJ, Parsons JL. Guardians of the genome: DNA damage and repair. Essays Biochem. 2020;64:683–685.
   PubMedGoogle Scholar
• Sobol RW, Horton JK, Kuhn R, et al. Requirement of mammalian DNA polymerase-beta in base-excision repair. Nature. 1996;379(6561):183–186.
   PubMed Web of Science ®Google Scholar
• Sobol RW, Wilson SH. Mammalian DNA beta-polymerase in base excision repair of alkylation damage. Prog Nucleic Acid Res Mol Biol. 2001;68:57–74.
   PubMedGoogle Scholar
• Sobol RW, Prasad R, Evenski A, et al. The lyase activity of the DNA repair protein beta-polymerase protects from DNA-damage-induced cytotoxicity. Nature. 2000;405(6788):807–810.
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–917.
   PubMed Web of Science ®Google Scholar
• Montaldi AP, Lima SCG, Godoy PRDV, et al. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. Oncol Rep. 2020;44(5):2275–2287.
   PubMed Web of Science ®Google Scholar
• Balvers RK, Lamfers MLM, Kloezeman JJ, et al. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells. J Transl Med. 2015;13.
   PubMed Web of Science ®Google Scholar
• Beard WA, Wilson SH. Structure and mechanism of DNA polymerase β. Biochemistry. 2014;53(17):2768–2780.
   PubMed Web of Science ®Google Scholar
• Krokan HE, Bjoras M. Base excision repair. Cold Spring Harb Perspect Biol. 2013;5(4):a012583.
   PubMed Web of Science ®Google Scholar
• Lawson MH, Cummings NM, Rassl DM, et al. Two novel determinants of etoposide resistance in small cell lung cancer. Cancer Res. 2011;71(14):4877–4887.
   PubMed Web of Science ®Google Scholar
• Rw S, M K, Kh A, et al. Base excision repair intermediates induce p53-independent cytotoxic and genotoxic responses. J Biol Chem. 2003;278:39951.
   PubMed Web of Science ®Google Scholar
• Sobol RW, Watson DE, Nakamura J, et al. Mutations associated with base excision repair deficiency and methylation-induced genotoxic stress. Proc Natl Acad Sci U S A. 2002;99(10):6860–6865.
   PubMed Web of Science ®Google Scholar
• Lavrik OI. PARPs' impact on base excision DNA repair. DNA Repair (Amst). 2020;93:102911.
   PubMed Web of Science ®Google Scholar
• Chiba N. Targeting DNA repair and DNA damage response in cancer therapy. Cancer Sci. 2021;112:220–220.
   Web of Science ®Google Scholar
• Barakat KH, Gajewski MM, Tuszynski JA. DNA polymerase beta (pol β) inhibitors: a comprehensive overview. Drug Discov Today. 2012;17(15–16):913–920.
   PubMed Web of Science ®Google Scholar
• Nixon AE, Sexton DJ, Ladner RC. Drugs derived from phage display: from candidate identification to clinical practice. mAbs. 2014;6(1):73–85.
   PubMed Web of Science ®Google Scholar
• Cao Y, Yang H, Zhou XL, et al. Selection and characterization of human PCSK9 antibody from phage displayed antibody library. Biochem Biophys Res Commun. 2015;463(4):712–718.
   PubMed Web of Science ®Google Scholar
• Chan JKC. The wonderful colors of the hematoxylin-eosin stain in diagnostic surgical pathology. Int J Surg Pathol. 2014;22(1):12–32.
   PubMed Web of Science ®Google Scholar
• Sarkissian T, Timmons A, Arya R, et al. Detecting apoptosis in drosophila tissues and cells. Methods. 2014;68(1):89–96.
   PubMed Web of Science ®Google Scholar
• Grau J, Gustafson KS, Pasha T, et al. Increased expression of y-H2AX in the proliferative stem cell compartment of the colon in ulcerative colitis: a marker of DNA damage. Mod Pathol. 2007;20:115a–116a.
   Web of Science ®Google Scholar
• Boice A, Bouchier-Hayes L. Targeting apoptotic caspases in cancer. Biochim Biophys Acta-Mol Cell Res. 2020;1867.
   PubMed Web of Science ®Google Scholar
• Omidfar K, Daneshpour M. Advances in phage display technology for drug discovery. Expert Opin Drug Discov. 2015;10(6):651–669.
   PubMed Web of Science ®Google Scholar
• Tan YY, Tian T, Liu WL, et al. Advance in phage display technology for bioanalysis. Biotechnol J. 2016;11(6):732–745.
   PubMed Web of Science ®Google Scholar
• Albertella MR, Lau A, O'Connor MJ. The overexpression of specialized DNA polymerases in cancer. DNA Repair (Amst). 2005;4(5):583–593.
   PubMed Web of Science ®Google Scholar
• Srivastava DK, Husain I, Arteaga CL, et al. DNA polymerase beta expression differences in selected human tumors and cell lines. Carcinogenesis. 1999;20(6):1049–1054.
   PubMed Web of Science ®Google Scholar
• Zhu W, Zhou L, Qian JQ, et al. Temozolomide for treatment of brain metastases: a review of 21 clinical trials. World J Clin Oncol. 2014;5(1):19–27.
   PubMedGoogle Scholar